CN102727479B - 视黄酸及其衍生物在制备防治动脉粥样硬化药物中的应用 - Google Patents
视黄酸及其衍生物在制备防治动脉粥样硬化药物中的应用 Download PDFInfo
- Publication number
- CN102727479B CN102727479B CN201210197440.1A CN201210197440A CN102727479B CN 102727479 B CN102727479 B CN 102727479B CN 201210197440 A CN201210197440 A CN 201210197440A CN 102727479 B CN102727479 B CN 102727479B
- Authority
- CN
- China
- Prior art keywords
- compound
- treatment groups
- atherosclerosis
- alkyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1(C)C(CCC(Br)=*C=CC=CC(O)=O)=C(C)CCC1 Chemical compound CC1(C)C(CCC(Br)=*C=CC=CC(O)=O)=C(C)CCC1 0.000 description 3
- JUXPWDKWFNFGLM-ARZXKRCTSA-N CCC/C(/CC(C)C(O)=O)=C/C=C/C=C/c1ccc(C(C)(C)CCC2(C)C)c2c1 Chemical compound CCC/C(/CC(C)C(O)=O)=C/C=C/C=C/c1ccc(C(C)(C)CCC2(C)C)c2c1 JUXPWDKWFNFGLM-ARZXKRCTSA-N 0.000 description 1
Abstract
Description
组别 | 主动脉斑块面积(mm2) | 主动脉总面积(mm2) | 比值(%) |
正常组 | 0 | 129.12±3.23 | 0 |
模型组 | 32.35±1.67 | 133.10±3.16 | 0.24±0.018 |
化合物1治疗组 | 13.87±1.78 | 137.63±5.66 | 0.12±0.024 |
化合物2治疗组 | 15.22±0.21 | 139.56±1.99 | 0.09±0.012 |
化合物3治疗组 | 15.62±2.84 | 136.11±1.61 | 0.11±0.015 |
化合物4治疗组 | 14.09±3.28 | 138.04±0.76 | 0.12±0.011 |
化合物5治疗组 | 16.63±1.57 | 133.63±3.58 | 0.09±0.023 |
化合物6治疗组 | 14.09±0.13 | 137.43±3.74 | 0.10±0.022 |
化合物7治疗组 | 15.64±2.15 | 131.07±5.36 | 0.11±0.024 |
化合物8治疗组 | 13.52±0.34 | 138.12±4.34 | 0.11±0.015 |
化合物9治疗组 | 16.08±3.04 | 130.76±2.98 | 0.09±0.012 |
化合物10治疗组 | 16.52±1.45 | 130.38±6.27 | 0.11±0.018 |
化合物11治疗组 | 14.91±2.44 | 137.42±1.65 | 0.10±0.017 |
化合物12治疗组 | 14.52±1.37 | 134.46±5.82 | 0.09±0.023 |
化合物13治疗组 | 16.02±0.06 | 138.96±0.28 | 0.10±0.022 |
化合物14治疗组 | 15.17±2.21 | 133.52±5.01 | 0.09±0.011 |
化合物15治疗组 | 13.42±0.27 | 136.01±4.23 | 0.09±0.023 |
化合物16治疗组 | 16.07±2.33 | 131.36±5.85 | 0.09±0.012 |
化合物17治疗组 | 14.12±0.24 | 136.14±0.62 | 0.11±0.024 |
化合物18治疗组 | 15.73±2.26 | 130.46±3.76 | 0.11±0.026 |
化合物19治疗组 | 15.24±2.42 | 135.53±0.62 | 0.10±0.012 |
化合物20治疗组 | 14.46±2.24 | 131.39±0.67 | 0.11±0.017 |
化合物21治疗组 | 14.03±1.39 | 133.56±4.06 | 0.11±0.015 |
化合物22治疗组 | 14.62±2.92 | 137.19±3.18 | 0.09±0.015 |
化合物23治疗组 | 13.57±2.53 | 137.47±3.59 | 0.09±0.019 |
化合物24治疗组 | 16.02±0.56 | 137.99±0.34 | 0.09±0.022 |
化合物25治疗组 | 14.94±0.12 | 132.91±0.59 | 0.11±0.016 |
化合物26治疗组 | 15.16±1.51 | 139.82±1.74 | 0.11±0.026 |
化合物27治疗组 | 16.55±0.78 | 136.03±5.44 | 0.10±0.017 |
化合物28治疗组 | 14.49±1.68 | 138.63±0.82 | 0.11±0.025 |
化合物29治疗组 | 15.12±0.19 | 139.58±5.86 | 0.11±0.024 |
化合物30治疗组 | 14.26±3.39 | 131.15±5.23 | 0.12±0.014 |
化合物31治疗组 | 13.42±2.76 | 136.32±2.94 | 0.12±0.017 |
化合物32治疗组 | 13.45±1.65 | 130.06±2.73 | 0.12±0.025 |
化合物33治疗组 | 14.64±2.17 | 133.34±1.38 | 0.11±0.026 |
化合物34治疗组 | 13.73±3.24 | 137.61±0.31 | 0.11±0.011 |
化合物35治疗组 | 13.46±2.07 | 137.01±2.27 | 0.11±0.015 |
化合物36治疗组 | 14.73±1.76 | 132.99±6.55 | 0.10±0.022 |
化合物37治疗组 | 13.24±0.07 | 138.52±2.23 | 0.12±0.015 |
化合物38治疗组 | 14.69±2.43 | 136.37±1.48 | 0.12±0.014 |
化合物39治疗组 | 13.54±2.12 | 131.31±3.73 | 0.11±0.013 |
化合物40治疗组 | 13.44±2.68 | 135.59±0.01 | 0.11±0.015 |
化合物41治疗组 | 13.35±0.05 | 138.19±0.51 | 0.11±0.016 |
化合物42治疗组 | 15.18±2.46 | 133.83±1.03 | 0.10±0.011 |
化合物43治疗组 | 15.76±1.23 | 139.65±6.57 | 0.10±0.017 |
化合物44治疗组 | 14.61±2.42 | 134.39±4.45 | 0.11±0.018 |
化合物45治疗组 | 13.32±1.32 | 132.25±3.62 | 0.11±0.011 |
化合物46治疗组 | 14.72±2.21 | 133.351±2.35 | 0.10±0.015 |
组别 | 内膜厚度(μm) | 中膜厚度(μm) | 内膜/中膜厚度比(%) |
正常组 | 111.46±18.72 | 358.75±19.72 | 31.06±3.25 |
模型组 | 253.63±20.52 | 369.24±15.63 | 57.39±3.43 |
化合物1治疗组 | 158.27±12.32 | 366.65±14.71 | 26.45±2.98 |
化合物2治疗组 | 153.19±11.02 | 361.92±9.04 | 29.01±6.97 |
化合物3治疗组 | 153.43±13.05 | 362.89±17.75 | 26.92±2.15 |
化合物4治疗组 | 156.75±12.32 | 356.07±12.98 | 24.52±4.23 |
化合物5治疗组 | 151.42±8.81 | 354.49±12.07 | 29.03±4.34 |
化合物6治疗组 | 147.46±8.05 | 362.91±13.39 | 27.13±3.96 |
化合物7治疗组 | 149.75±13.35 | 361.55±16.39 | 26.51±2.54 |
化合物8治疗组 | 147.03±10.72 | 353.57±17.77 | 28.79±2.72 |
化合物9治疗组 | 146.18±10.95 | 356.41±16.23 | 26.96±4.97 |
化合物10治疗组 | 148.28±9.52 | 350.44±12.87 | 26.92±4.29 |
化合物11治疗组 | 159.31±11.88 | 358.08±12.59 | 25.34±4.98 |
化合物12治疗组 | 155.19±11.42 | 360.93±11.88 | 24.23±4.93 |
化合物13治疗组 | 147.86±13.19 | 367.41±13.55 | 24.71±2.06 |
化合物14治疗组 | 155.74±9.28 | 366.99±9.89 | 28.67±3.83 |
化合物15治疗组 | 148.19±11.87 | 356.88±11.73 | 25.44±4.59 |
化合物16治疗组 | 148.32±8.56 | 363.25±17.27 | 29.36±6.77 |
化合物17治疗组 | 158.53±9.05 | 361.31±16.06 | 24.72±2.66 |
化合物18治疗组 | 159.58±11.61 | 366.84±9.69 | 24.76±6.76 |
化合物19治疗组 | 155.69±13.62 | 360.48±12.76 | 24.31±2.06 |
化合物20治疗组 | 154.38±12.53 | 360.99±17.35 | 24.13±5.84 |
化合物21治疗组 | 147.27±12.36 | 359.16±12.27 | 25.53±5.65 |
化合物22治疗组 | 158.01±12.96 | 353.82±16.38 | 28.18±5.46 |
化合物23治疗组 | 157.17±10.64 | 359.21±12.53 | 28.36±4.45 |
化合物24治疗组 | 153.99±11.18 | 366.52±14.25 | 28.39±3.53 |
化合物25治疗组 | 145.57±12.77 | 364.33±9.96 | 28.97±2.56 |
化合物26治疗组 | 149.72±11.21 | 353.72±9.82 | 26.92±6.53 |
化合物27治疗组 | 147.21±9.26 | 357.26±12.56 | 26.72±3.17 |
化合物28治疗组 | 154.13±11.77 | 354.89±9.73 | 24.27±2.28 |
化合物29治疗组 | 158.31±8.52 | 367.28±16.79 | 25.52±2.45 |
化合物30治疗组 | 151.62±13.78 | 367.16±12.63 | 26.04±3.34 |
化合物31治疗组 | 152.26±10.13 | 365.72±14.93 | 28.09±3.78 |
化合物32治疗组 | 156.91±10.43 | 351.39±14.58 | 28.27±4.97 |
化合物33治疗组 | 147.93±9.67 | 365.02±11.84 | 26.15±6.25 |
化合物34治疗组 | 159.79±11.66 | 358.61±17.63 | 26.95±6.16 |
化合物35治疗组 | 158.32±11.14 | 352.42±14.64 | 24.03±3.41 |
化合物36治疗组 | 154.32±12.29 | 350.42±13.66 | 25.34±2.42 |
化合物37治疗组 | 155.47±8.43 | 367.22±10.99 | 24.08±5.11 |
化合物38治疗组 | 155.43±10.27 | 350.54±12.65 | 29.49±3.49 |
化合物39治疗组 | 159.44±13.38 | 354.39±10.55 | 27.27±5.74 |
化合物40治疗组 | 151.68±9.54 | 352.15±10.31 | 28.01±3.98 |
化合物41治疗组 | 157.72±10.53 | 352.42±12.94 | 26.79±3.09 |
化合物42治疗组 | 152.98±12.97 | 360.52±11.82 | 25.02±3.15 |
化合物43治疗组 | 150.99±10.84 | 351.99±15.36 | 28.35±6.51 |
化合物44治疗组 | 148.82±8.46 | 360.05±12.34 | 25.45±3.62 |
化合物45治疗组 | 152.57±7.86 | 365.23±13.31 | 26.43±4.42 |
化合物46治疗组 | 155.85±7.43 | 354.13±10.36 | 27.32±5.65 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210197440.1A CN102727479B (zh) | 2012-06-14 | 2012-06-14 | 视黄酸及其衍生物在制备防治动脉粥样硬化药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210197440.1A CN102727479B (zh) | 2012-06-14 | 2012-06-14 | 视黄酸及其衍生物在制备防治动脉粥样硬化药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102727479A CN102727479A (zh) | 2012-10-17 |
CN102727479B true CN102727479B (zh) | 2014-05-21 |
Family
ID=46984249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210197440.1A Active CN102727479B (zh) | 2012-06-14 | 2012-06-14 | 视黄酸及其衍生物在制备防治动脉粥样硬化药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102727479B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219888A (en) * | 1992-03-31 | 1993-06-15 | American Cyanamid Company | Use of retinoids for the treatment of coronary artery disease |
-
2012
- 2012-06-14 CN CN201210197440.1A patent/CN102727479B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219888A (en) * | 1992-03-31 | 1993-06-15 | American Cyanamid Company | Use of retinoids for the treatment of coronary artery disease |
Non-Patent Citations (3)
Title |
---|
all-trans-Retinoic Acid Increases Nitric Oxide Synthesis by Endothelial Cells,A Role for the Induction of Dimethylarginine Dimethylaminohydrolase;Vinod Achan et al;《Circulation Research》;20020307;第90卷;764-769页 * |
Bennie J. Bench,et al.Synthesis and cellular effects of cycloterpenals:Cyclohexadienal-based activators of neurite outgrowth.《Bioorganic & Medicinal Chemistry》.2008,第16卷 * |
VinodAchanetal.all-trans-RetinoicAcidIncreasesNitricOxideSynthesisbyEndothelialCells A Role for the Induction of Dimethylarginine Dimethylaminohydrolase.《Circulation Research》.2002 |
Also Published As
Publication number | Publication date |
---|---|
CN102727479A (zh) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101674810A (zh) | 针对癌细胞和癌相关成纤维细胞的靶向剂 | |
CN102389419A (zh) | 吲哚-3-甲醇、二吲哚甲烷及其衍生物在制备防治动脉粥样硬化药物中的应用 | |
Fang et al. | Pharmacokinetics of enrofloxacin in allogynogenetic silver crucian carp, Carassius auratus gibelio | |
Ding et al. | A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors | |
Terzi et al. | Pharmacokinetics of danofloxacin in rainbow trout after different routes of administration | |
WO2009155439A2 (en) | Use of nitrated lipids for treatment of side effects of toxic medical therapies | |
CN102088971A (zh) | 生育三烯酚组合物预防癌症的用途 | |
Corum et al. | Pharmacokinetic/pharmacodynamic integration of marbofloxacin after oral and intravenous administration in rainbow trout (Oncorhynchus mykiss) | |
KR20150028299A (ko) | 야누스 키나제 (jak) 억제제 투여요법 | |
CN108619168A (zh) | 一种糖尿病治疗药物及其制备与应用 | |
CN102727479B (zh) | 视黄酸及其衍生物在制备防治动脉粥样硬化药物中的应用 | |
CN107041880A (zh) | 磷酸二酯酶4抑制剂ZL-n-91在制备抗肺癌增殖与转移药物中的应用 | |
CN107569485A (zh) | 一种治疗braf抑制剂耐药型黑色素瘤的复方制剂 | |
CN101355948A (zh) | 用于治疗增殖性疾病的Roscovitine和HDAC抑制剂的组合 | |
CN103536922B (zh) | 酰基辅酶a:胆固醇酰基转移酶‑2抑制剂在抑制肝癌生长中的应用 | |
CN102438620A (zh) | 肿瘤治疗的化合物和组合药物的配方 | |
WO2014191989A1 (en) | Conjugate of a taxane and biotin and uses thereof | |
WO2016127068A1 (en) | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound | |
CN107130021B (zh) | Ccat1长链非编码rna及其小分子抑制剂在肝细胞癌治疗方面的应用 | |
CN102727477B (zh) | 视黄酸及其衍生物在制备防治糖尿病药物中的应用 | |
Nakagawa et al. | Inhibition of methylazoxymethanol acetate initiation of colon carcinogenesis in rats by treatment with the poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide | |
JP2017518967A (ja) | 進行した非アルコール性脂肪性肝炎の治療方法 | |
WO2021192726A1 (ja) | コリン取り込み抑制剤、細胞死誘導剤、抗がん剤、およびその用途 | |
CN104004056A (zh) | 一种关于Cyclin D蛋白抑制剂多肽及其应用 | |
CN102727476B (zh) | 视黄酸及其衍生物在制备防治骨质疏松药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170525 Address after: 230088, Hefei province high tech Zone Innovation Avenue 2800, innovation industry park two, E District 1, B, building 2, Anhui Patentee after: Hefei Jian Jian Pharmaceutical Technology Co., Ltd. Address before: 230088 No. 26, phreatic East Road, hi tech Zone, Anhui, Hefei Patentee before: Hefei Botai Pharmaceutical Biotechnology Development Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170823 Address after: 242300 Anhui city of Ningguo province conch road and Biyun Road intersection port eco industrial park Patentee after: Ningguo Wu Yue medical science and Technology Co Ltd Address before: 230088, Hefei province high tech Zone Innovation Avenue 2800, innovation industry park two, E District 1, B, building 2, Anhui Patentee before: Hefei Jian Jian Pharmaceutical Technology Co., Ltd. |